Observational studyPediatric nephrology (Berlin, Germany)2019

Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.

Andrew P Maxted et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.